The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 06, 2017

Filed:

Dec. 16, 2011
Applicants:

Justin Pritchard, Boston, MA (US);

Douglas A. Lauffenburger, Cambridge, MA (US);

Michael Hemann, Cambridge, MA (US);

Inventors:

Justin Pritchard, Boston, MA (US);

Douglas A. Lauffenburger, Cambridge, MA (US);

Michael Hemann, Cambridge, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); G01N 33/50 (2006.01); C12N 15/10 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1079 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5023 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/178 (2013.01);
Abstract

In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents. In another aspect, the invention is directed to a method of determining whether a patient population treated with a first agent would benefit from a treatment using the first agent in combination with one or more additional agents. In yet another aspect, the invention is directed to method of determining whether a formulation of one or more agents maintains a mechanism of action of the one or more agents when unformulated.


Find Patent Forward Citations

Loading…